Short Communication Relationship between Content and Activity of Cytochrome P450 and Induction of Heterocyclic Amine DNA Adducts in Human Liver Samples In vivo and In vitro

This study was designed to estimate a correlation between metabolic activation phenotypes and formation of DNA adducts by heterocyclic amines (HCA) in 15 liver samples from healthy donors. The correlation between the amount of endogenous DNA adducts and the content of cytochrome P450 in human liver samples in vivo was statistically significant at r = 0.71 and P < 0.005. Furthermore, the isolated human liver microsomes were treated in vitro with two HCAs, 2-amino1-methyl-6-phenylimidazo[4,5-b]pyridine (PhIP) and 2-amino-9H-pyrido[2,3-b]indole (AAC), which have been recognized to induce two DNA adducts: 3V,5V-diphosphate-N-(2V-deoxyguanosin-8-yl)-PhIP (3V,5V-pdGpC8-PhIP) and 3V,5V-diphosphate-N-(2V-deoxyguanosin -8-yl)-AAC (3V,5V-pdGp-C8-AAC). The correlations between the amount of DNA adducts induced by both compounds in vitro and the content of cytochrome P450 in human microsomes are statistically significant at r = 0.69 and r = 0.62 (P < 0.001), respectively. Furthermore, the level of DNA adducts after treatment withPhIP and AAC correlated with the activities of three isozymes of cytochrome P450: CYP1A1, CYP1A2, and CYP3A4. Therefore, three chemical inhibitors were used in the experiments: ellipticine against CYP1A1, furafylline against CYP1A2, and troleandomycin against CYP3A4. The highest inhibition levels in the formation of 3V,5V-pdGp-C8-PhIP and 3V,5V-pdGp-C8AAC adducts were estimated to occur in the presence of furafylline at 56% and 69%, respectively. Ellipticine was involved in the inhibition of 40% of 3V,5V-pdGC8-PhIP adducts and in only 18% of the inhibition of 3V,5V-pdGp-C8-AAC adducts. Troleandomycin did not significantly inhibit the formation of 3V,5V-pdGp-C8PhIP adducts under these conditions, but it inhibited the formation of 31% of the 3V,5V-pdGpC8-AAC adducts. We conclude that the formation of DNA adducts can be used as a relevant marker of interindividual variability in the metabolic activation of HCAs in humans. (Cancer Epidemiol Biomarkers Prev 2004; 13(6):1071–8)